ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. BRAIN Biotech AG's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was -13.26%.
As of today (2026-06-30), BRAIN Biotech AG's WACC % is 12.64%. BRAIN Biotech AG's ROIC % is -10.72% (calculated using TTM income statement data).
BRAIN Biotech AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.
BRAIN Biotech AG (HAM:BNN) ROIC % Explanation
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROIC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, BRAIN Biotech AG's WACC % is 12.64%. BRAIN Biotech AG's ROIC % is -10.72% (calculated using TTM income statement data).
BRAIN Biotech AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
BRAIN Biotech AG ROIC % Related Terms
BRAIN Biotech AG ROIC % Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's ROIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, BRAIN Biotech AG's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG ROIC % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's ROIC % distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's ROIC % falls into.
Note:
The Operating Income data used here is four times the quarterly (Mar. 2026) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG (HAM:BNN) has a ROIC % of -13.26% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on BRAIN Biotech AG and its competitors.
Is BRAIN Biotech AG's ROIC % too high?
BRAIN Biotech AG's current ROIC % is -13.26%. Overall, BRAIN Biotech AG has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's ROIC % compare to LIN and SHW?
BRAIN Biotech AG's ROIC % of -13.26% can be compared against companies in the Chemicals industry. The industry median ROIC % is 4.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Chemicals company?
The median ROIC % among Chemicals companies is 4.46, based on 1,581 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on BRAIN Biotech AG and its competitors. For the Chemicals industry, the median ROIC % is 4.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current ROIC % is -13.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.56, compared to a current price of €2.83 — trading 10.5% above its estimated fair value. The current ROIC % is -13.26%. BRAIN Biotech AG's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current ROIC % is -13.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.83 is trading 10.5% above its estimated GF Value™ of €2.56.
GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.
Key valuation signals for HAM:BNN:
ROIC %: -13.26%
GF Value™: €2.56 vs. price of €2.83 (10.5% above fair value)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
69GF Score
Get the complete analysis for HAM:BNN
ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
